AlgiPharma was founded in August 2006, based on research and development carried out by FMC BioPolymer AS and the Biopolymer Foundation at the Norwegian University of Science and Technology in Trondheim, Norway.
The company owns or licenses all relevant patents upon which the technology platform and products are developed.
AlgiPharma’s objective is to develop and market selected products and therapies and to license technology and product candidates to suitable partners.
The company is supported by national and international research programs and grants. We work closely with a number of highly recognized academic institutions and research organizations in Europe and USA.
The company is privately owned.
|
|
